Preclinical biotech developing next‑generation T cell engagers that target multiple peptide–MHC cancer antigens to treat solid tumors. Platform enables single drugs to recognize multiple tumor-specific targets to retain potency despite antigen loss and heterogeneity, with a proprietary format that provides antibody-like stability and scalable manufacturing.